Valuation: Actavis PLC

Market Cap 6.37TCr 5.58TCr 5.15TCr 4.76TCr 9.03TCr 6,09500Cr 9.21TCr 62TCr 24TCr 2,98300Cr 24TCr 23TCr 10,35500Cr P/E 2018
-8.76x
P/E 2019 -11.9x
Enterprise Value 8.1TCr 7.1TCr 6.56TCr 6.06TCr 11TCr 7,75200Cr 12TCr 79TCr 31TCr 3,79400Cr 30TCr 30TCr 13,17000Cr EV / Sales 2018
4.24x
EV / Sales 2019 4.98x
Free-Float
99.9%
Yield 2018
2.15%
Yield 2019 1.55%
08/04 Allergan Aesthetics Opens New Ami Training Center in Austin CI
31/03 Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting CI
30/03 Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting CI
19/03 Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions CI
04/03 Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients CI
12/11 Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence CI
25/25/25 AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai CI
19/25/19 Allergan Aesthetics Unveils Its Newest Hydration Hero CI
30/25/30 U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance CI
12/25/12 Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training CI
19/24/19 BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) CI
27/24/27 Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator CI
27/24/27 Allergan Aesthetics Debuts Alle Payment Plans CI
Manager TitleAgeSince
Director of Finance/CFO 56 01/12/2016
President 55 08/05/2020
Director TitleAgeSince
Director/Board Member 55 08/05/2020
Director/Board Member - 08/05/2020
Director/Board Member - 08/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%+2.02%+56.34%+168.30% 1,10200Cr
-1.44%+3.71%+69.07%+65.13% 64TCr
-0.75%+0.67%+33.18%+87.92% 45TCr
-1.35%+0.63%+30.26%+26.28% 34TCr
-0.86%+0.99%+39.36%+40.85% 30TCr
-0.71%-0.54%+28.98%+48.27% 29TCr
-1.31%+2.72%-26.76%-39.82% 22TCr
-0.03%+1.84%+23.90%+63.75% 20TCr
-0.40%+7.82%+22.29%+79.44% 17TCr
Average -0.97%+2.47%+30.74%+60.01% 41.18TCr
Weighted average by Cap. -1.14%+2.14%+41.63%+86.10%

Financials

2018 2019
Net sales 1.58TCr 1.38TCr 1.28TCr 1.18TCr 2.24TCr 1,51200Cr 2.28TCr 15TCr 5.97TCr 74TCr 5.93TCr 5.8TCr 2,56800Cr 1.61TCr 1.41TCr 1.3TCr 1.2TCr 2.28TCr 1,54100Cr 2.33TCr 16TCr 6.09TCr 75TCr 6.04TCr 5.91TCr 2,61700Cr
Net income -509.64Cr -447.01Cr -412.69Cr -381.36Cr -722.83Cr -49TCr -737.3Cr -4.96TCr -1.93TCr -24TCr -1.91TCr -1.87TCr -83TCr -527.1Cr -462.32Cr -426.82Cr -394.42Cr -747.59Cr -50TCr -762.56Cr -5.13TCr -1.99TCr -25TCr -1.98TCr -1.94TCr -86TCr
Net Debt 2.19TCr 1.92TCr 1.77TCr 1.64TCr 3.1TCr 2,09600Cr 3.17TCr 21TCr 8.28TCr 1,02600Cr 8.22TCr 8.04TCr 3,56100Cr 1.73TCr 1.52TCr 1.4TCr 1.29TCr 2.45TCr 1,65700Cr 2.5TCr 17TCr 6.55TCr 81TCr 6.5TCr 6.36TCr 2,81500Cr
Logo Actavis PLC
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Employees
-